ADMA Biologics Faces Securities Fraud Class Action Over Revenue Claims

The complaint, spearheaded by the law firm Glancy Prongay Wolke & Rotter LLP, targets ADMA Biologics for allegedly misleading shareholders regarding the company's fiscal health. According to the court filings, the firm claims that management failed to disclose undisclosed related party transactions and utilized channel stuffing—a practice of inflating sales figures by shipping excess inventory to distributors—to create a false appearance of sustained revenue growth.

Beyond revenue manipulation, the lawsuit asserts that the company suffered from deficient internal controls, rendering previous public statements about its business operations materially inaccurate. Shareholders seeking to participate in the litigation or those wishing to serve as a lead plaintiff must contact Charles Linehan at Glancy Prongay Wolke & Rotter LLP before the August deadline. Investors who choose not to act remain part of the class action by default unless they opt to retain independent counsel.